The European Hematology Association (EHA)

An observational study of ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma in French centers (REMIX) further defined the patient and disease characteristics and safety profile with this regimen; efficacy data are still maturing. Read More ›

This pivotal trial (OPTIMISMM) subgroup analysis supports use of pomalidomide, bortezomib, and low-dose dexamethasone for lenalidomide-refractory patients regardless of age, prior stem-cell transplant status, or presence of high-risk cytogenetic abnormalities. Read More ›

An ongoing study of venetoclax plus daratumumab and dexamethasone ± bortezomib in patients with relapsed/refractory multiple myeloma demonstrated tolerable safety and clinically meaningful overall response rate (92%-96%), particularly among those with t(11;14). Read More ›

Addition of daratumumab to ixazomib/dexamethasone in second-line post-lenalidomide relapsed multiple myeloma (phase 1 portion of the ongoing DARIA study) resulted in a >70% overall response rate. Read More ›

Adding isatuximab to pomalidomide-dexamethasone treatment in RRMM patients with preexisting plasmacytomas resulted in improved median progression-free survival and rates of overall response and very good partial response with a manageable safety profile. Read More ›

A retrospective analysis of ICARIA-MM and TCD14079 studies shows adding isatuximab to pomalidomide-dexamethasone improved progression-free survival and increased rates of overall response and very good partial response or better in patients with gain(1q21). Read More ›

Adding elotuzumab to bortezomib/lenalidomide/dexamethasone as induction therapy for newly diagnosed multiple myeloma patients in the GMMG-HD6 study failed to increase the rates of very good partial response and complete response after 4 cycles. Read More ›

Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›

In newly diagnosed transplant-eligible multiple myeloma patients who achieved very good partial response or better in the Italian FORTE study, there was strong concordance among 3 minimal residual disease–assessing techniques. Read More ›

Post-induction ixazomib as maintenance therapy in patients newly diagnosed with multiple myeloma not treated with front-line stem-cell transplantation (TOURMALINE-MM4 trial) resulted in median progression-free survival of 17.4 months with tolerable safety. Read More ›